To include your compound in the COVID-19 Resource Center, submit it here.

Aegerion buys Myalept from AZ for $325M

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) acquired global rights outside of three Asian territories to Myalept metreleptin from

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE